Skip to Content
End of Year Sale. Save up to thirty five percent off sitewide.End of Year Sale. Save up to thirty five percent off sitewide.

Annals of Oncology

An official Journal of the European Society for Medical Oncology and the official journal of the Japanese Society of Medical Oncology

An official Journal of the European Society for Medical Oncology and the official journal of the Japanese Society of Medical Oncology

Editor :
Fabrice André ,
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncolog ...view more
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.

Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape.

Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.

Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape.